Notable Labs Raises $10M in Series A Financing

Sep 06, 2017

|

NEW YORK (360Dx) – San Francisco-based Notable Labs today announced that it has raised $10 million in Series A funding, which it will put toward building its technology platform and team, as well as clinical feasibility studies related to blood cancers.

The firm provides a drug-testing service for oncologists identifying treatment options for blood-cancer patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Featured White Papers

Analysis of Inflammatory Plasma Biomarkers in Cancer Patient Samples using Simoa CorPlex Human Cytokine Panel 1

A High-Performance Solution Combining CleanPlex OncoZoom Cancer Hotspot Panel and SOPHiA AI for Rapid Characterization of Somatic Mutations

Oct

24

Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov

14

Featured Webinar

High-Performance Variant Detection in Somatic Cancer Testing with an Integrated NGS Solution

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

Dec

02

Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Menu